It’s tempting to think that legalizing drug importation would immediately give U.S. consumers access to medicines at the prices available in other developed countries. In reality, however, the Safe Importation Action Plan would expose American consumers to significant health risks while achieving meager cost reductions, if any at all. Visit Real Clear Health to lean […]
In partnership with the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS) has recently proposed that certain pharmaceuticals should be cleared for import from Canada. Although the proposal seeks to lower prices for consumers, it poses critical unintended risks to both American businesses and patients. To read why, visit Townhall.
In an effort to reverse the continuing rise of prescription drug prices, the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS) are mulling the idea of allowing drug imports from Canada. Their so-called “Safe Importation Action Plan,” however, is a misnomer—the policy could expose countless Americans to potentially deadly […]
Congress should preserve public quality standards for biologic drugs
Last month, federal officials announced the Safe Importation Action Plan to legalize the importation of foreign drug products, including from Canada. However, the biggest concern with is proposal is that drug importation will expose American patients to unsafe, adulterated and counterfeit medicines from all over the world. To learn more, you can read this op-ed […]
If you missed part one of our new webinar series you can watch it HERE now. On Tuesday, we gathered leading policy experts to tackle some of the toughest issues facing consumers in tech policy. Panelists discussed how future consumer protections are shaping up, from privacy legislation and what to do about robocalls, to the […]
Biosimilars are the grand experiment. If the biosimilar experiment succeeds, competition will lead to lower prices and increase access for patients. However, if biosimilar competition does not advance the result may be price controls. This could decrease the incentive to innovate and lead to fewer new drugs being developed. Biologics are among the highest priced […]
Getting rid of mandatory public standards for biologics would undermine public trust and jeopardize the quality of medicines available to patients here in Maine, without tangible benefits to consumers. Your can read about this at The Portland Press Herald.
Most short-term home sharing rentals provide a supplementary income for people looking to give travelers a local experience. It is good for tourism and saves consumers money. Yet, as this op-ed points out, some shortsighted policymakers and regulators are trying to overregulate the home sharing industry at the expense of homeowners, tourists, and the local […]